T cell surface glycoprotein CD3 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13T cell surface glycoprotein CD3 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P07766. Start with neoplasm, then reuse UniProt P07766 as the stable protein anchor across project notes and exports.
Start with neoplasm, then reuse UniProt P07766 as the stable protein anchor across project notes and exports.
T cell surface glycoprotein CD3 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 11 linked drugs remain visible in the same block.
Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BLINATUMOMAB, CATUMAXOMAB, ELRANATAMAB, EPCORITAMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyT-cell surface glycoprotein CD3 epsilon chain
Review this target as T cell surface glycoprotein CD3, mapped to UniProt P07766. ChEMBL maps the protein component as T-cell surface glycoprotein CD3 epsilon chain. Sequence length is 207 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats T cell surface glycoprotein CD3 as ChEMBL target CHEMBL2364168, mapped to UniProt P07766. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether T cell surface glycoprotein CD3 is the right protein anchor across sources, using UniProt P07766 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 11 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | T cell surface glycoprotein CD3 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P07766 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | T-cell surface glycoprotein CD3 epsilon chain |
| UniProt Accession | P07766 |
| Component Type | Protein |
| Sequence Length | 207 aa |
T-cell surface glycoprotein CD3 epsilon chain
Review this target as T cell surface glycoprotein CD3, mapped to UniProt P07766. ChEMBL maps the protein component as T-cell surface glycoprotein CD3 epsilon chain. Sequence length is 207 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
T cell surface glycoprotein CD3 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.
Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BLINATUMOMAB, CATUMAXOMAB, ELRANATAMAB, EPCORITAMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.